Fischer K, et al. - Through an open-label, phase 3 trial, carried out on 432 patients, researchers investigated the efficacy of BCL2 inhibitor venetoclax in combination with other agents in patients with chronic lymphocytic leukemia. They assessed fixed-duration treatment with venetoclax and obinutuzumab in patients with previously untreated CLL and coexisting conditions. Venetoclax–obinutuzumab group showed significantly higher progression-free survival at 24 months vs the chlorambucil–obinutuzumab group. Patients with unmutated immunoglobulin heavy-chain genes and with TP53 deletion, mutation, or both also saw this benefit. Grade 3 or 4 neutropenia occurred in 52.8% of patients in the venetoclax–obinutuzumab group and in 48.1% of patients in the chlorambucil–obinutuzumab group; grade 3 or 4 infections occurred in 17.5% and 15.0%, respectively.